8-K: Gritstone Bio Announces Promising Preliminary Data for Personalized Cancer Vaccine in Colorectal Cancer

Gritstone Bio reported encouraging preliminary progression-free survival data from its Phase 2 study of the GRANITE cancer vaccine in combination with immune checkpoint blockade for metastatic colorectal cancer.

Summary

• Gritstone Bio announced preliminary data from its Phase 2 study of the GRANITE cancer vaccine in combination with immune checkpoint blockade for patients with metastatic microsatellite stable colorectal cancer.
• The study included 104 patients, with 67 patients included in the preliminary analysis (39 in the GRANITE arm and 28 in the control arm).
• Preliminary progression-free survival (PFS) data showed a trend of improvement in GRANITE recipients, with a hazard ratio of 0.82 in all patients.
• In a high-risk group (defined by baseline ctDNA above the median), the hazard ratio was 0.52, indicating a 48% relative risk reduction of progression or death with GRANITE compared to the control.
• Median PFS in the high-risk group was 12 months for the GRANITE arm and 7 months for the control arm.
• Short-term ctDNA response data was uninformative due to an unexpected continuation of ctDNA drop beyond induction chemotherapy.
• Long-term ctDNA data showed a correlation with clinical benefit and favored GRANITE patients.
• The GRANITE vaccine was generally well-tolerated, with most adverse events being mild and typical of potent vaccines.
• No patients discontinued the trial due to adverse events.
• Mature PFS data is expected in the third quarter of 2024, and overall survival data is expected in the first half of 2025.

Sentiment

Score: 7

Explanation: The document presents positive preliminary data, particularly in the high-risk group, and the vaccine is well-tolerated. However, the early stage of the data and the high patient attrition rate temper the overall optimism.

Positives

• The GRANITE arm showed a trend of improvement in progression-free survival (PFS) compared to the control arm.
• The high-risk group experienced a significant 48% relative risk reduction of progression or death with GRANITE.
• Median PFS in the high-risk group was 12 months for the GRANITE arm, compared to 7 months for the control arm.
• Long-term ctDNA data correlated with clinical benefit and favored GRANITE patients.
• The vaccine was well-tolerated with no patients discontinuing the trial due to adverse events.

Negatives

• Short-term ctDNA response data was uninformative due to an unexpected continuation of ctDNA drop beyond induction chemotherapy.
• 36 patients left the study prior to randomized treatment, primarily due to early progressive disease or withdrawal of consent.

Risks

• The preliminary nature of the data means that the results could change as the study progresses.
• The study has a high rate of patient attrition with 36 patients leaving the study prior to randomized treatment.
• The short-term ctDNA data was uninformative, which could indicate challenges in using this biomarker for early response assessment.
• The hazard ratio for all patients was 0.82, which is not statistically significant and may not be clinically meaningful.

Future Outlook

The company expects to provide mature PFS data in the third quarter of 2024 and overall survival data in the first half of 2025.

Management Comments

• The company announced preliminary progression-free survival (PFS), long-term circulating tumor DNA (ctDNA) and tolerability data from the Phase 2 portion of its randomized, open-label Phase 2/3 study.

Industry Context

This announcement is relevant to the field of immuno-oncology and personalized cancer vaccines, where there is a growing interest in developing treatments that target specific tumor characteristics. The results are being watched closely by investors and competitors in the space.

Comparison to Industry Standards

• The reported median PFS of 12 months in the high-risk group for the GRANITE arm compares favorably to historical data for standard of care treatments in metastatic colorectal cancer, which often show median PFS in the range of 6-9 months.
• Companies like BioNTech and Moderna are also developing mRNA-based cancer vaccines, but their clinical trial data is not directly comparable due to differences in patient populations and study designs.
• The use of ctDNA as a biomarker is becoming increasingly common in cancer trials, and the long-term correlation between ctDNA response and PFS observed in this study is consistent with industry trends.

Stakeholder Impact

• Shareholders may react positively to the promising preliminary data.
• Patients with metastatic colorectal cancer may have a new treatment option in the future.
• The company's employees may be motivated by the positive results.

Next Steps

• The company will continue to monitor patients in the study.
• Mature PFS data is expected in the third quarter of 2024.
• Overall survival data is expected in the first half of 2025.

Key Dates

Keywords

Gritstone Bio, GRANITE, cancer vaccine, colorectal cancer, metastatic, progression-free survival, ctDNA, immune checkpoint blockade, clinical trial, Phase 2